Amgen Inc. $AMGN Shares Bought by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN) by 52.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 7,367 shares of the medical research company’s stock after purchasing an additional 2,525 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Amgen were worth $2,079,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the second quarter valued at approximately $27,000. Evelyn Partners Investment Management LLP acquired a new position in Amgen in the 2nd quarter valued at $32,000. Howard Hughes Medical Institute purchased a new position in shares of Amgen during the 2nd quarter worth $32,000. Quaker Wealth Management LLC boosted its holdings in shares of Amgen by 200.0% during the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after purchasing an additional 240 shares during the last quarter. Finally, Cloud Capital Management LLC purchased a new stake in shares of Amgen in the third quarter valued at $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Market commentary highlighting recent share-strength and valuation checks has drawn fresh investor attention, supporting momentum off strong YTD and 1‑year returns. Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate
• Positive Sentiment: Multiple articles argue Amgen is a long-term value/dividend play, reinforcing buy-and-hold interest from income and value-focused investors. Why Amgen (AMGN) is a Top Value Stock for the Long-Term (Zacks)
• Positive Sentiment: Amgen scheduled a presentation at the TD Cowen Health Care Conference (March 2), giving management a platform to update on commercial outlook and the MARITIME trial timetable — a likely near‑term liquidity for investor sentiment. AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
• Neutral Sentiment: Short interest data posted shows zero shares and a short-interest ratio of 0.0 days — this appears to be a reporting anomaly and doesn’t provide a clear signal on bearish positioning.
• Neutral Sentiment: Feature pieces and retrospectives on long‑term returns (Benzinga, MSN) boost narrative momentum but are not new fundamental catalysts. If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today
• Negative Sentiment: Barclays initiated coverage with an Equal Weight rating and a $185 price target — a relatively conservative view that could cap upside and prompt some profit‑taking or more cautious positioning among institutional holders. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

Amgen Price Performance

Shares of NASDAQ AMGN opened at $382.87 on Wednesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The company has a market capitalization of $206.39 billion, a price-to-earnings ratio of 26.91, a PEG ratio of 3.76 and a beta of 0.46. The business has a 50-day moving average of $345.41 and a 200-day moving average of $317.87.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter last year, the company earned $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 70.84%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. The Goldman Sachs Group upped their price target on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday, February 4th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. DZ Bank upped their price objective on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Finally, Argus lifted their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Amgen has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.